Despite its long history of use, just how ECT works is not clear. While the jolts cause brain-wide generalized seizure, recent thinking is that the electrical reset does not affect all brain circuits uniformly. Depression and schizophrenia respond to ECT, but not anxiety, OCD, or eating disorders. The adverse effects of ECT are quite specific too, affecting mainly memory and sparing other domains like executive function and language.

In addition, some clinical domains, including anhedonia, amotivation, and suicidal behavior respond ECT no matter what disorder they occur with. “We think that there are specific circuits, such as those related to reward, that are particularly sensitive to the seizures, so that the ECT produces plastic changes in those, but not in other places, that support the therapy’s benefit. Now, if I can learn how ECT does its magic, then I could I could try to facilitate those same changes with TMS," Camprodon says.


To sort out the circuitry that’s affected by ECT, Camprodon’s group is using multimodal imaging to map brain connectomics. Studies involving structural MRI, functional MRI, and diffusion tractography noninvasively determine brain anatomy, function and connectivity. They also use EEG to look at patterns of neuronal activation in nodes and circuits.

So far, they’ve identified circuits that support the response to ECT for depression, and now are trying to look individually at dimensions like anhedonia, amotivation and suicide. “If we can learn first how to improve amotivation or anhedonia in depression, we could use these strategies to treat amotivation more globally in a number of neurologic and psychiatric disorders--in frontotemporal dementia, in Alzheimer’s disease, in patients with neural Lyme disease or multiple sclerosis,” Camprodon says.

One domain that Camprodon is especially interested in targeting is executive function, the brain circuit that supports organization, planning and mental focus. Problems with executive function occur across the spectrum of neurologic and psychiatric conditions, and are among the most disabling symptoms in many conditions. There are no good treatments to improve cognition, says Camprodon, but the anatomy of the circuits that support good executive function is known. In a transdiagnostic study, his group is evaluating TDCS to treat executive dysfunction in patients with traumatic brain injury, frontotemporal dementia, ADHD, schizophrenia, depression and bipolar disorder.

If Camprodon’s work seems to blur the borders between neurology and psychiatry, that’s by design, he says. “We’ve moved from a traditional description of neuropsychiatry as a subspecialty for patients with neurological disorders who presented with psychiatric symptoms. We still do that, but now we use a broader definition. It’s not just who we see, but how we see them—with a circuit-centered approach to evaluating and treating each patient, no matter their diagnosis.”

Back to HCB News

Alzheimers/Neurology Homepage